康弘药业：公司KH110（治疗阿尔茨海默症）正在按计划进行临床研究

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) is progressing with clinical research for its drug KH110, aimed at treating Alzheimer's disease, according to the company's statement on December 18 [2]. Group 1 - The clinical research for KH110 is proceeding as planned [2]. - The company acknowledges the inherent uncertainties in drug development, clinical trials, and regulatory approvals [2]. - Investors are advised to make cautious decisions and be aware of investment risks [2].